Expanded Access to Tipifarnib

NCT04809233 · clinicaltrials.gov ↗

AVAILABLE

Status

INDUSTRY

Sponsor class

Conditions

HRAS Mutations or Peripheral T Cell Lymphoma (PTCL)

Interventions

DRUG: Tipifarnib

Sponsor

Kura Oncology, Inc.